

Long-acting PrEP and adults

Issue:

- Feasibility issues with conducting adequately powered noninferiority trials for PrEP (N=@24,000) and the desire to economize sample size

Discussion:

- How best can STIs be used as a marker of risk in PrEP trials?
 - What STIs should be evaluated and for which population
 - Any ideas for other data sources go collect STI and HIV incidence data?
- How does adherence affect trial results and how should adherence data be used to assess overall efficacy results?
- What other data can be used to assess efficacy?